You are on page 1of 10

Hartalega Holdings

HEALTH CARE & PHARMACEUTICALS

HTHB.KL HART MK

EQUITY RESEARCH

Raising TP to MYR4.70; maintain Reduce 

June 17, 2013 Rating Remains Target price Increased from 4.15 Closing price June 12, 2013 Potential downside

Valuations unattractive as dominant NBR segment sees keener competition
Action: Raising TP to MYR4.70; maintain Reduce We revise our TP upwards to MYR4.70 from MYR4.15, incorporating our updated raw material price assumptions, capacity estimates and exchange rate forecasts. Taking into account the new inputs, we adjust upward our FY13F/FY14F net profit by 6.4%/9.5%. While we acknowledge Hartalega’s unparalleled efficiencies, we think that valuations are lofty in light of a more crowded NBR glove market, which should see pricing power come under pressure, in our view. Catalyst: Margin downtrend likely as ASP continues to weaken We note that all major glovemakers are expanding aggressively in the nitrile (NBR) market, with additional capacity of c.15bn pcs slated to be put on-stream by the four main players alone in calendar 2013. While demand is likely to remain strong for rubber gloves, we think heightened competition will continue to prompt manufacturers to lower ASPs as customers enjoy better bargaining power. Thus we remain cautious on NBR-focused glovemakers as we believe that margins are likely to see a downward trend in the near term. Valuation: Expensive amid stiffer competition in the NBR space Hartalega shares currently trade at 19.1x FY14F EPS of 33.04sen, which is a lofty valuation in our view, amid intensifying competition and declining ROEs. We arrive at our TP of MYR4.70 by pegging its FY14F EPS of 33.04sen to a target multiple of 14.2x – the average one-year forward P/E it has traded at in the past 12 months. We do not use a long-term average as Hartalega saw a structural break in valuations back in 2012.

Reduce
MYR 4.70 MYR 6.30 -25.4%

Anchor themes We expect healthy long-term demand outlook due to growing healthcare awareness and an aging population worldwide. Nonetheless, with competition set to increase in the years ahead, we see lower pricing power for glovemakers. Nomura vs consensus Our TP is 16% below consensus on expectations of lower margins moving forth and TP being pegged to a lower P/E multiple; we think the stock is expensive at current levels.
Research analysts Malaysia Health Care & Pharmaceuticals Celeste Yap - NSM celeste.yap@nomura.com +603 2027 6894 Bineet Banka - NSFSPL bineet.banka@nomura.com +91 22 4053 3784

31 Mar Currency (MYR)

FY13 Actual Old

FY14F New Old

FY15F New Old

FY16F New

Revenue (mn) Reported net profit (mn) Normalised net profit (mn) FD normalised EPS FD norm. EPS growth (%) FD normalised P/E (x) EV/EBITDA (x) Price/book (x) Dividend yield (%) ROE (%) Net debt/equity (%)

1,032 235 235 31.67c 15.0 19.9 13.1 6.0 2.0 33.9

1,165 236 236 32.29c 6.5 N/A N/A N/A N/A 28.8

1,209 251 251 33.04c 4.3 19.1 12.1 5.2 2.4 29.8

1,376 254 254 34.73c 7.6 N/A N/A N/A N/A 26.1

1,351 279 279 35.47c 7.4 17.8 10.7 4.6 2.5 27.9 N/A N/A N/A N/A

1,636 322 322 39.72c 12.0 15.9 9.1 4.0 2.8 27.4 0.2

net cash net cash net cash

1.7 net cash

Source: Company data, Nomura estimates

See Appendix A-1 for analyst certification, important disclosures and the status of non-US analysts.

Key company data: See page 2 for company data and detailed price/index chart.

2 46.47c 1.7 7.9 1.2 26.8 19.Nomura | Hartalega Holdings June 17.2 2.3 3.4/3.0 6.209 -832 377 -53 324 377 -53 324 -1 FY15F 1.8 29.9 7.6 10.1 31.04c 33.8 2.5 15.8 17.4 10.9 11.1 14.0 14.8 20.65c 27.9 2.38 0.7 6.18   13 .1 2.72c 39.6 22.0 64.8 14.53c 0.145 492 -69 423 505 -82 423 -1 Source: ThomsonReuters.9 15.6 4.5 17.67c 1.7 23.0 45.0 12.0 15. dividend payout policy of more than 45% 26.0 27.7 22.0 27.1 10.10c 31.1 4.2 38.4 5.85 0.9 16.65c 27.9 14.1 14.0 Source: Thomson Reuters.8 20.7 45.4 30.8 22.3 45.7 23.83 1.0 13.1 15.0 22.1 4.6 5.9 17.4 31.8 17.04c 33.2 31.9 31.6 19.9 32.1 19. 2013 Key data on Hartalega Holdings Income statement (MYRmn)  Year-end 31 Mar Revenue Cost of goods sold Gross profit SG&A Employee share expense Operating profit EBITDA Depreciation Amortisation EBIT Net interest expense Associates & JCEs Other income Earnings before tax Income tax Net profit after tax Minority interests Other items Preferred dividends Normalised NPAT Extraordinary items Reported NPAT Dividends Transfer to reserves Valuation and ratio analysis Reported P/E (x) Normalised P/E (x) FD normalised P/E (x) FD normalised P/E at price target (x) Dividend yield (%) Price/cashflow (x) Price/book (x) EV/EBITDA (x) EV/EBIT (x) Gross margin (%) EBITDA margin (%) EBIT margin (%) Net margin (%) Effective tax rate (%) Dividend payout (%) Capex to sales (%) Capex to depreciation (x) ROE (%) ROA (pretax %) Growth (%) Revenue EBITDA EBIT Normalised EPS Normalised FDEPS Per share Reported EPS (MYR) Norm EPS (MYR) Fully diluted norm EPS (MYR) Book value per share (MYR) DPS (MYR) Source: Company data.8 22.1 15.5 3.4 16.9 26.47c 35.9 30.4 21.1 11.1 5.1 32.2 36.0 30.6 2.7 27.8 17.0 5.8 14.9 45.3 11.7 19.57 0.5 31.04c 1.9 25.7 51.9 29.032 -731 301 6 307 339 -32 307 -1 FY14F 1.2 31.0 9.1 27.5 45.0 18.1 17.6 12.473.9 6. Nomura research Notes 22.0 66.5 19.7 22.5 29.72c 1. Nomura research   (%) Absolute (MYR) Absolute (USD) Relative to index Market cap (USDmn) Estimated free float (%) 52-week range (MYR) 3-mth avg daily turnover (USDmn) Major shareholders (%) Hartalega Industries Sdn Bhd Budi Tenggara Sdn Bhd 1M 3M 12M 10.8 13.72c 39.16 39.0 23.12 33.2 12.3 We expect margins and returns above industry average.351 -930 421 -58 363 430 -68 363 -1 FY16F 1.6 33.1 14.9 21.3 3.15 35.47c 35.6 10.0 17.1 17.9 15.9 4.4 1.05 0.7 31.21 0.0 21. Nomura estimates Relative performance chart (one year) FY12 931 -634 297 -36 260 289 -29 260 -2 FY13 1.0 7.4 19.31 258 -57 201 0 306 -71 235 0 323 -72 251 0 361 -82 279 0 421 -99 322 0 201 201 -91 110 235 235 -91 143 251 251 -113 138 279 279 -126 153 322 322 -145 177 50.8 36.4 7.636 -1.1 5.1 19.1 11.5 17.8 1.8 0.10c 32.2 31.3 2.4 15.7 22.7 12.13 32.0 44.6 5.6 19.

8 51.87 270.8 45.0 43.3 44.9 46.Nomura | Hartalega Holdings June 17.8 33.5 38.096 13 93 15 121 8 0 50 179 1 0 379 537 FY15F 38 0 176 125 0 338 1 876 7 49 1.2 54.7 14 .489 13 129 15 157 9 0 50 216 2 0 403 868 Notes Reducing cash pile in line with high capex.9 46.4 45.42 339.48 310.63 285.7 40.082 1.8 47. long-term capacity expansion plans which should see capacity more than triple upon completion (estimated completed in FY21F) Balance sheet (MYRmn)  As at 31 Mar Cash & equivalents Marketable securities Accounts receivable Inventories Other current assets Total current assets LT investments Fixed assets Goodwill Other intangible assets Other LT assets Total assets Short-term debt Accounts payable Other current liabilities Total current liabilities Long-term debt Convertible debt Other LT liabilities Total liabilities Minority interest Preferred stock Common stock Retained earnings Proposed dividends Other equity and reserves Total shareholders' equity Total equity & liabilities Liquidity (x) Current ratio Interest cover Leverage Net debt/EBITDA (x) Net debt/equity (%) Activity (days) Days receivable Days inventory Days payable Cash cycle Source: Company data. Nomura estimates FY12 163 0 117 98 0 378 0 370 0 10 758 13 60 12 85 12 0 41 138 1 0 183 437 FY13 182 0 125 87 0 394 1 486 7 49 936 8 93 15 115 4 0 50 170 1 0 367 399 FY14F 73 0 156 117 0 346 1 693 7 49 1.8 net cash net cash net cash net cash net cash net cash net cash net cash 0.7 2.42 149.2 42.043 7 49 1.9 55.2 50.5 42.9 38. expected higher earnings should move Hartalega back to net cash position by FY16F 620 758 766 936 916 1. 2013 Cashflow (MYRmn)  Year-end 31 Mar EBITDA Change in working capital Other operating cashflow Cashflow from operations Capital expenditure Free cashflow Reduction in investments Net acquisitions Reduction in other LT assets Addition in other LT liabilities Adjustments Cashflow after investing acts Cash dividends Equity issue Debt issue Convertible debt issue Others Cashflow from financial acts Net cashflow Beginning cash Ending cash Ending net debt Source: Company data.8 2.271 1.8 3.271 13 101 15 129 8 0 50 188 1 0 391 691 FY16F 19 0 212 158 0 389 1 1.2 44.2 2.01 0.096 1. Nomura estimates   FY12 289 -37 -52 200 -35 165 0 0 0 0 -25 140 -87 0 0 0 -7 -94 46 117 163 -139 FY13 339 38 -59 317 -18 299 0 0 0 0 -176 123 -99 0 0 0 -5 -104 19 163 182 -170 FY14F 377 -61 -73 244 -261 -17 0 0 0 0 0 -17 -113 0 0 0 20 -92 -110 182 73 -52 FY15F 430 -20 -83 327 -250 77 0 0 0 0 0 77 -126 12 0 0 1 -112 -35 73 38 -16 FY16F 505 -42 -100 363 -250 113 0 0 0 0 0 113 -145 12 0 0 1 -132 -18 38 19 3 Notes Significantly higher capex for large.489 4.271 1.2 36.7 42.

20 5.92 Note: Nitrile prices are grossed up to the same solid content as latex for comparison purpose. However.64 2. albeit slightly.95 2016F 6. We have previously attached a target multiple of 12.4%/9. with a small customer base of 450 names (>100 active ones). 22: Input assumptions changes Input assumptions (period average) Latex prices (MYR/kg) Old New Nitrile prices (MYR/kg) Old New MYR/USD Old New Source: Nomura estimates 2014F 6. capacity expansion is likely to be muted in FY14F.70. We arrive at our new TP of MYR4. We also understand from management that Hartalega’s long-term expansion programme – the Next Generation Integrated Glove Manufacturing Complex (NGC) – has been delayed by eight months due to some setback in getting various approvals from the relevant authorities.19 6.10 5. we change our target multiple to reflect the continuous improvement in the company’s operations and potential diversification as previously discussed. adding production capacity by nearly 30bn pcs upon completion. as new production lines from the NGC will only start coming into operations from August 2014. We expect construction of the NGC to be completed by FY20F. We expect margins to trend downwards We note that Hartalega’s ASPs have been trending south in the past few quarters. geographical region and customer base. while at the same time updating our raw material price assumptions and exchange rate forecasts.23 6. North American and European markets (>85% revenue). after its structural break in 2012.2x target one-year forward P/E.05 2015F 6. reflecting both a weaker raw material price and also lower profit margins. we were impressed by the company’s ability to constantly upgrade its products and production processes via on-going R&D efforts. on the back of the previously mentioned two factors.13 5. As highlighted in the earlier section.95 3.35 6. we are thus cautious of its earnings growth prospects in the near term as pricing power is likely to come under pressure. As a result. which is the average multiple Hartalega has traded at in the past 12 months. and thus view its intention to diversify positively. We note that Hartalega is currently highly concentrated on the NBR gloves segment (94% revenue). 2013 Raising TP to MYR4.77 per share. as per management guidance. construction of the new production facility will be sped up by building two production plants concurrently. Management acknowledges the fact that stiffer competition in the NBR market has prompted industry players to lower prices.35 6. maintain Reduce After a recent meeting with management.70 by pegging our revised FY14F EPS of 33.04sen to a higher 14.88 2. 15 . we adjust our FY14F/FY15F earnings estimates upward by 6.89 2.96 6.78 2.56 2. While such a strategy has worked well for Hartalega in the past. Taking into account Hartalega’s improved line speed and revised capacity expansion plans. in our view. Hartalega is highly concentrated in the NBR segment. which provides an intrinsic value of MYR4. and expects itself to continue dropping prices in the rest of the year. Our changes of inputs are summarised in the table below: Fig. We also learned that Hartalega is looking for ways to diversify itself in terms of product offerings. Our P/E-based TP is well supported by our 10-year DCF valuation with cashflows discounted back to June 2013. we think that the lack of diversification of its revenue source potentially posts inherent risks to the company.25 5.8x for Hartalega – 1SD above its 3-year mean.5%.Nomura | Hartalega Holdings June 17.

• Higher/lower-than-expected pass-on rates of cost inflation/savings. Nomura research Source: Bloomberg.6 Mean = 10. owing to shrinking EBIT margins and lower asset turnover. Nomura research While we believe that Hartalega deserves to trade at a premium to sector average P/E multiple. • Further weakening of NBR raw material prices.1 May 09 May 10 May 11 May 12 2 May 08 May 09 May 10 May 11 May 12 Source: Bloomberg. significant capacity expansion plans which will continue to boost capacity and earnings. a PEG ratio of 2. We further note that we expect Hartalega to see ROE decline from 36% in FY12. we opine that its current valuations are expensive – particularly given the upcoming keen competition in the NBR segment which has previously been dominated by Hartalega. 34% in FY13 down to 27% in FY16F. 23: Historical P/E band chart MYR 7 6 5 4 3 2 1 0 May 08 17x 14x 11x 8x 5x Fig.2 on our estimates suggests that current lofty valuations appear to be somewhat unjustified for its growth potentials.4 +1SD = 13. • Faster-than-expected completion of its NGC expansion plans. Risks to our view Upside risks • New. As well. 2013 Fig. 16 . or innovative product types which could push up margins. 24: Historical one-year forward P/E P/E (x) 18 16 14 12 10 8 6 4 -1SD = 7.Nomura | Hartalega Holdings June 17.

or any of its affiliates or subsidiaries.95 For explanation of ratings refer to the stock rating keys located after chart(s) Valuation Methodology Our target price of MYR4. hereby certify (1) that the views expressed in this Research report accurately reflect my personal views about any or all of the subject securities or issuers referred to in this Research report. 3) faster-than-expected completion of its NGC expansion plans.57 Price date Stock rating Sector rating Disclosures 04-Jun-2013 Reduce Not rated Hartalega Holdings (HART MK) Rating and target price chart (three year history) MYR 5.77.6% and terminal growth of 2%. significant capacity expansion plans which will continue to boost capacity and earnings.04sen. 17 .. and 4) further weakening of NBR raw material prices. is or will be directly or indirectly related to the specific recommendations or views expressed in this Research report and (3) no part of my compensation is tied to any specific investment banking transactions performed by Nomura Securities International.15 Closing price 4.2x. and may refer to one or more Nomura Group companies. Inc. Materially mentioned issuers Issuer Hartalega Holdings Ticker HART MK Price MYR 5. 2013 Appendix A-1 Analyst Certification I. Celeste Yap. discounted back to June 2013 on a WACC of 7. 2) higher/lower-than-expected pass-on rates of cost inflation/savings. Our 10-year DCF valuation.70 is pegged to a one-year forward P/E of 14. Inc. Issuer Specific Regulatory Disclosures The term "Nomura Group" used herein refers to Nomura Holdings. Risks that may impede the achievement of the target price Upside risks to our view include 1) new.57 (04-Jun-2013) Reduce (Sector rating: Not rated) Date 09-Jan-13 09-Jan-13 Rating Target price Reduce 4. or innovative product types which could push up margins. Nomura International plc or any other Nomura Group company. provides a fair value of MYR4.95 4.Nomura | Hartalega Holdings June 17. (2) no part of my compensation was. on FY14F EPS of 33.

A 'Neutral' rating means most stocks in the sector have (or the weighted average recommendation of the stocks under coverage is) a neutral absolute recommendation. is classified as a Hold rating.com/research/globalresearchportal/pages/disclosures/disclosures. for purposes of mandatory disclosures. A 'Bearish' rating means most stocks in the sector have (or the weighted average recommendation of the stocks under coverage is) a negative absolute recommendation. the Target Price will equal the analyst's 12-month intrinsic valuation of the stock. and trading securities held by a research analyst account. the non-US analysts listed at the front of this report are not registered/qualified as research analysts under FINRA/NYSE rules. and NIplc are generally engaged in the trading of swaps and other derivative products. and may not be subject to FINRA Rule 2711 and NYSE Rule 472 restrictions on communications with covered companies.com/research. a portion of which is generated by Investment Banking activities. are classified as a Buy rating. Investors should not expect continuing or additional information from Nomura relating to such securities and/or companies. Industry Specialists do not contribute in any manner to the content of research reports in which their names appear. the fair value will equal the analyst's assessment of the current intrinsic fair value of the stock using an appropriate valuation methodology such as discounted cash flow or multiple analysis. A 'Reduce' recommendation indicates that potential downside is 5% or more.com/research/globalresearchportal/pages/disclosures/disclosures. etc. 11% have been assigned a Reduce rating which. Any authors named in this report are research analysts unless otherwise indicated. A 'Bearish' stance. please email grpsupport@nomura. SECTORS A 'Bullish' rating means most stocks in the sector have (or the weighted average recommendation of the stocks under coverage is) a positive absolute recommendation. Marketing Analysts may also contribute to research reports in which their names appear and publish research on their sector.Current Price) / Current Price.current price)/current price. indicates that the analyst expects the sector to outperform the Benchmark during the next 12 months. Bloomberg. Securities and/or companies that are labelled as 'Not rated' or shown as 'No rating' are not in regular research coverage of the Nomura entity identified in the top banner. Europe: Dow Jones STOXX 600. which can be accessed at: http://go. (“NDPI”) and Nomura International plc. Unless otherwise noted. NGFP. indicates that the rating. may not be associated persons of NSI.nomuranow. A 'Buy' recommendation indicates that potential upside is 15% or more. subject to limited management discretion. indicates that the analyst expects the stock to outperform the Benchmark over the next 12 months. but not limited to. Reuters and ThomsonOne.Nomura | Hartalega Holdings June 17. Marketing Analysts identified in some Nomura research reports are research analysts employed by Nomura International plc who are primarily responsible for marketing Nomura’s Equity Research product in the sector for which they have coverage. unless otherwise stated in the valuation methodology. Middle East and Africa. NDPI. based on an appropriate valuation methodology such as discounted cash flow. public appearances. As at 31 March 2013. Distribution of ratings (Global) The distribution of all ratings published by Nomura Global Equity Research is as follows: 43% have been assigned a Buy rating which. Important disclosures may be read at http://go.aspx or requested from Nomura Securities International.aspx. (“NIplc”) are registered with the Commodities Futures Trading Commission and the National Futures Association (NFA) as swap dealers. 40% of companies with this rating are investment banking clients of the Nomura Group*. for purposes of mandatory disclosures. Nomura Global Financial Products Inc. on 1-877-865-5752. indicates that the analyst expects the sector to perform in line with the Benchmark during the next 12 months. multiple analysis. Global Emerging Markets (ex-Asia): MSCI Emerging Markets ex-Asia. The analysts responsible for preparing this report have received compensation based upon various factors including the firm's total revenues.. 2013 Important Disclosures Online availability of research and conflict-of-interest disclosures Nomura research is available on www. Inc.nomuranow. when Nomura is acting in an advisory capacity in a merger or strategic transaction involving the company. indicates that the analyst expects the stock to underperform the Benchmark over the next 12 months. A rating of 'Suspended' indicates that the rating and target price have been suspended temporarily to comply with applicable regulations and/or firm policies in certain circumstances including when Nomura is acting in an advisory capacity in a merger or strategic transaction involving the subject company. US and Latin America The rating system is a relative system indicating expected performance against a specific benchmark identified for each individual stock. 46% have been assigned a Neutral rating which. indicates that the analyst expects the stock to perform in line with the Benchmark over the next 12 months. for purposes of mandatory disclosures. A 'Neutral' stance. subject to limited management discretion. If you have any difficulties with the website. etc. In most cases. Global Emerging Markets (ex-Asia): MSCI Emerging Markets ex-Asia. *The Nomura Group as defined in the Disclaimer section at the end of this report. Explanation of Nomura's equity research rating system in Japan and Asia ex-Japan STOCKS Stock recommendations are based on absolute valuation upside (downside). Benchmarks are as follows: United States/Europe: please see valuation methodologies for explanations of relevant benchmarks for stocks. Explanation of Nomura's equity research rating system in Europe. Analysts may also indicate absolute upside to target price defined as (fair value . A rating of 'Reduce'. In most cases. 18 . 48% of companies with this rating are investment banking clients of the Nomura Group*. A rating of 'Suspended'. are classified as a Sell rating. (“NGFP”) Nomura Derivative Products Inc. Capital IQ.nomuranow. STOCKS A rating of 'Buy'. A rating of 'Neutral'.com for help. any of which may be the subject of this report. indicates that the analyst expects the sector to underperform the Benchmark during the next 12 months. 23% of companies with this rating are investment banking clients of the Nomura Group*. Benchmarks are as follows: United States: S&P 500. Factset. target price and estimates have been suspended temporarily to comply with applicable regulations and/or firm policies in certain circumstances including. Industry Specialists identified in some Nomura International plc research reports are employees within the Firm who are responsible for the sales and trading effort in the sector for which they have coverage. which is defined as (Target Price . MarkitHub. SECTORS A 'Bullish' stance. A 'Neutral' recommendation indicates that potential upside is less than 15% or downside is less than 5%.

The achievement of any target price may be impeded by general market and macroeconomic trends. if discussed. reflects in part the analyst's estimates for the company's earnings. 19 . and by other risks related to the company or the market. 2013 Target Price A Target Price.Nomura | Hartalega Holdings June 17. and may not occur if the company's earnings differ from estimates.

OR (II) REDISTRIBUTED WITHOUT THE PRIOR WRITTEN CONSENT OF A MEMBER OF NOMURA GROUP. Without limiting any of the foregoing. By accepting to receive this document. including ratings. UK. including. re-disseminated or used to create any financial products. Moreover. Fax: +91 22 4037 4111. The user assumes the entire risk of any use made of this information. by NSI. (‘NIHK’). completeness. by any person other than those authorised to do so into Saudi Arabia or in the UAE or to any person other than ‘Authorised Persons’. under the US Securities Exchange Act of 1934. Clients outside of the US may access the Nomura Research Trading Ideas platform (Retina) at http://go. In Singapore. incidental. If verification is required. whether as a result of differing time horizons. completeness. Madrid Branch (‘NIplc. of issuers or securities mentioned herein. INF231299034. OR DUPLICATED IN ANY FORM. Nomura Group. Worli. but not limited to. 20 . Any failure to comply with these restrictions may constitute a violation of the laws of the UAE or Saudi Arabia. that may be associated with any investment decision. AND WE ARE NOT SOLICITING ANY ACTION BASED UPON IT. are subject to change without notice. PHOTOCOPIED. Tel: +91 22 4037 4037. Korea (Information on Nomura analysts registered with the Korea Financial Investment Association ('KOFIA') can be found on the KOFIA Intranet at http://dis. including any indices. Malaysia. any warranties of merchantability or fitness for a particular purpose or use. including tax advice. Mumbai. Investors should consider this document as only a single factor in making their investment decision and. Taipei Branch (‘NITB’). The sender therefore does not accept liability for any errors or omissions in the contents of this document. (‘NSL’). may not be offered or sold in the US or to US persons unless they have been registered under the 1933 Act. This document may contain information obtained from third parties. Ltd. in such case. compensatory. or losses (including lost income or profits and opportunity costs) in connection with any use of their content. or for the results obtained from the use of such content. The term "Nomura Group" used herein refers to Nomura Holdings. Madrid’). Any comments or statements made herein are those of the author(s) and may differ from views held by other parties within Nomura Group. corrupted. or except in compliance with an exemption from the registration requirements of the 1933 Act. This document has also been approved for distribution in Malaysia by NSM. ‘Exempt Persons’ or ‘Institutions’ located in Saudi Arabia or to clients other than 'professional clients' in the UAE. Any MSCI sourced information in this document is the exclusive property of MSCI Inc. including ratings. Clients should consider whether any advice or recommendation in this report is suitable for their particular circumstances and. Shivsagar Estate. Where the information contains an indication of future performance. be redistributed to persons who are 'retail clients' for such purposes. exemplary. arrive late or incomplete. deal as principal. ‘CNS Thailand’ next to an analyst’s name on the front page of a research report indicates that the analyst is employed by Capital Nomura Securities Public Company Limited (‘CNS’) to provide research assistance services to NSL under a Research Assistance Agreement. simulations are based on models and simplifying assumptions which may oversimplify and not reflect the future distribution of returns. This document has been approved for distribution in Australia by NAL. and. NIplc is authorised by the Prudential Regulation Authority (‘PRA’). Nomura Group produces a number of different types of research product including. Nomura Singapore Ltd. therefore. Without prior written permission of MSCI. this will be separately disclosed within the specific issuer disclosures. Annie Besant Road. This document is intended only for investors who are 'eligible counterparties' or 'professional clients' for the purposes of applicable regulations in the UK.nomuranow. financial situations. with the sole or joint contributions of one or more Nomura entities whose employees and their respective affiliations are specified on page 1 herein or identified elsewhere in the document. (‘NAL’). please request a hard-copy version.T. Third party content providers do not guarantee the accuracy. Inc. such as e-mail. Reproduction and distribution of third party content in any form is prohibited except with the prior written permission of the related third party. regulated by the Australian Securities and Investment Commission ('ASIC') and holder of an Australian financial services licence number 246412. its affiliates and any third party involved in. Neither this document nor any copy thereof may be taken or transmitted or distributed. Taiwan. agent. NIplc or any other member of Nomura Group. ('NSI'). timeliness or availability of any information. and is a member of the London Stock Exchange. Nomura Group does not provide tax advice. this document has been distributed by NSL. Unless prohibited by the provisions of Regulation S of the 1933 Act. any of its affiliates or any third party involved in. P. ‘Exempt Persons’ or ‘Institutions’ (as defined by the Capital Markets Authority) in the Kingdom of Saudi Arabia (‘Saudi Arabia’) or to clients other than 'professional clients' (as defined by the Dubai Financial Services Authority) in the United Arab Emirates (‘UAE’) by Nomura Saudi Arabia. This document has been approved for distribution in the UK and European Economic Area as investment research by NIplc. This document has not been approved for distribution to persons other than ‘Authorised Persons’. BY ANY MEANS. special or consequential damages. you represent that you are not located in Saudi Arabia or that you are an ‘Authorised Person’. Nomura Financial Advisory and Securities (India) Private Limited (‘NFASL’). or income derived from. Nomura Group is under no duty to update this document. punitive. THIS MATERIAL IS: (I) FOR YOUR PRIVATE INFORMATION. where it concerns securities. Conflicts of Interest. or take into account the particular investment objectives. including ratings from credit ratings agencies such as Standard & Poor’s. this document. Indonesia. directors and employees. Third party content providers shall not be liable for any direct. Singapore (Registration number 197201440E. Level 11. Unless governing law permits otherwise. To the maximum extent permissible all warranties and other assurances by Nomura group are hereby excluded and Nomura Group shall have no liability for the use. SEBI Registration No: BSE INB011299030. or any of its affiliates or subsidiaries and may refer to one or more Nomura Group companies including: Nomura Securities Co. regulated by the Financial Conduct Authority and the PRA. regardless of the cause. directly or indirectly. Nomura Group does not warrant or represent that the document is accurate. accuracy. They do not address the suitability of securities or the suitability of securities for investment purposes. Nomura Group manages conflicts with respect to the production of research through its compliance policies and procedures (including. and are not responsible for any errors or omissions (negligent or otherwise).400 018. NSL accepts legal responsibility for the content of this document. NSE INB231299034. and/or. (‘MSCI’).kr). Where the activity of market maker is carried out in accordance with the definition given to it by specific laws and regulations of the US or other jurisdictions. which accepts responsibility for its contents in accordance with the provisions of Rule 15a-6. this information and any other MSCI intellectual property may not be reproduced. ('NSC') Tokyo. recommendations contained in one type of research product may differ from recommendations contained in other types of research product. or related to. but not limited to. misuse.or. lost. and may not. or distribution of this information. expert or institutional investors as defined by the Securities and Futures Act (Chapter 289). the investment. Different groups of clients may receive different products and services from the research department depending on their individual requirements. among others. including the opinions and estimates contained herein. Credit ratings are statements of opinions and are not statements of fact or recommendations to purchase hold or sell securities. or needs of individual investors. MSCI. complete. This information is provided on an "as is" basis. indirect. Nomura Securities Malaysia Sdn. Opinions or estimates expressed are current opinions as of the original publication date appearing on this material and the information. Nomura International (Hong Kong) Ltd. Hong Kong. 2013 Disclaimers This document contains material that has been prepared by the Nomura entity identified at the top or bottom of page 1 herein. Nomura Australia Ltd. futures and foreign exchange. India (Registered Address: Ceejay House. reliable. The securities described herein may not have been registered under the US Securities Act of 1933 (the ‘1933 Act’). Japan. MSCI and the MSCI indexes are services marks of MSCI and its affiliates. Nomura Financial Investment (Korea) Co. fit for any particular purpose or merchantable and does not accept liability for any act (or decision not to act) resulting from use of this document and related data. (II) NOT TO BE CONSTRUED AS AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY SECURITY IN ANY JURISDICTION WHERE SUCH OFFER OR SOLICITATION WOULD BE ILLEGAL.. Chinese Wall and Confidentiality policies) as well as through the maintenance of Chinese walls and employee training. or have long or short positions in. to the extent permitted by applicable law and/or regulation. direct or indirect. Third party content providers give no express or implied warranties. methodologies or otherwise. or in connection with. regulated by the Monetary Authority of Singapore). Plot F. INE 231299034. Recipients of this document in Singapore should contact NSL in respect of matters arising from. India. US. any transaction should be executed via a Nomura entity in your home jurisdiction. MCX: INE261299034) and NIplc. NIHK. this material is distributed in the US.. costs. which may arise as a result of electronic transmission. in no event shall MSCI. or related to. may. (‘NFIK’). or buy or sell. the report should not be viewed as identifying or suggesting all risks. Ltd. or options or other derivative instruments based thereon. BUT HAS NOT BEEN INDEPENDENTLY VERIFIED BY NOMURA GROUP. Certain securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of. as such. computing or compiling the information have any liability for any damages of any kind. expenses. Nomura International plc ('NIplc'). a US-registered broker-dealer. NO PART OF THIS MATERIAL MAY BE (I) COPIED. which is authorized and regulated in Australia by the ASIC. issued by their foreign affiliates in respect of recipients who are not accredited. This document has been approved by NIHK. as the case may be.kofia. destroyed. if any. New York. fundamental analysis. Nomura Securities International. or contain viruses. then such transmission cannot be guaranteed to be secure or error-free as information could be intercepted. and should not be relied on as investment advice. quantitative analysis and short term trading ideas. commodities or instruments. Bhd.com/equities/tradingideas/retina/ Figures presented herein may refer to past performance or simulations based on past performance which are not reliable indicators of future performance. legal fees. merchantability or fitness for a particular purpose with respect to any of this information. Nomura Group publishes research product in a number of different ways including the posting of product on Nomura Group portals and/or distribution directly to clients. computing or compiling the information hereby expressly disclaim all warranties of originality. seek professional advice. Inc. If this document has been distributed by electronic transmission. (‘NSM’). or otherwise. Australia (ABN 48 003 032 513). an ‘Exempt Person’ or an ‘Institution’ in Saudi Arabia or that you are a 'professional client' in the UAE and agree to comply with these restrictions. for distribution in Hong Kong by NIHK. AND (III) BASED UPON INFORMATION FROM SOURCES THAT WE CONSIDER RELIABLE. and/or its officers. if appropriate. which is regulated by the Hong Kong Securities and Futures Commission. Dr. CNS is not a Nomura entity. Nomura Group companies may also act as market maker or liquidity provider (within the meaning of applicable regulations in the UK) in the financial instruments of the issuer. Nomura Indonesia (‘PTNI’). Mumbai. This document does not constitute a personal recommendation within the meaning of applicable regulations in the UK. such forecasts may not be a reliable indicator of future performance.Nomura | Hartalega Holdings June 17. the securities.

2013 21 .Nomura | Hartalega Holdings Additional information is available upon request and disclosure information is available at the Nomura Disclosure web page: http://go..aspx Copyright © 2013 Nomura International (Hong Kong) Ltd. June 17. All rights reserved.nomuranow.com/research/globalresearchportal/pages/disclosures/disclosures.